7qu0: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==X-ray structure of FAD domain of NqrF of Klebsiella pneumoniae== | ==X-ray structure of FAD domain of NqrF of Klebsiella pneumoniae== | ||
<StructureSection load='7qu0' size='340' side='right'caption='[[7qu0]]' scene=''> | <StructureSection load='7qu0' size='340' side='right'caption='[[7qu0]], [[Resolution|resolution]] 1.62Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7QU0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7QU0 FirstGlance]. <br> | <table><tr><td colspan='2'>[[7qu0]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7QU0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7QU0 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7qu0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7qu0 OCA], [https://pdbe.org/7qu0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7qu0 RCSB], [https://www.ebi.ac.uk/pdbsum/7qu0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7qu0 ProSAT]</span></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=F2L:~{N}-[2,6-bis(fluoranyl)phenyl]ethanamide'>F2L</scene>, <scene name='pdbligand=FAD:FLAVIN-ADENINE+DINUCLEOTIDE'>FAD</scene></td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/NADH:ubiquinone_reductase_(Na(+)-transporting) NADH:ubiquinone reductase (Na(+)-transporting)], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=7.2.1.1 7.2.1.1] </span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7qu0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7qu0 OCA], [https://pdbe.org/7qu0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7qu0 RCSB], [https://www.ebi.ac.uk/pdbsum/7qu0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7qu0 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | |||
[[https://www.uniprot.org/uniprot/NQRF_KLEP7 NQRF_KLEP7]] NQR complex catalyzes the reduction of ubiquinone-1 to ubiquinol by two successive reactions, coupled with the transport of Na(+) ions from the cytoplasm to the periplasm. The first step is catalyzed by NqrF, which accepts electrons from NADH and reduces ubiquinone-1 to ubisemiquinone by a one-electron transfer pathway. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Over the last two decades, fragment-based drug discovery (FBDD) has emerged as an effective and efficient method to identify new chemical scaffolds for the development of lead compounds. X-ray crystallography can be used in FBDD as a tool to validate and develop fragments identified as binders by other methods. However, it is also often used with great success as a primary screening technique. In recent years, technological advances at macromolecular crystallography beamlines in terms of instrumentation, beam intensity and robotics have enabled the development of dedicated platforms at synchrotron sources for FBDD using X-ray crystallography. Here, the development of the Fast Fragment and Compound Screening (FFCS) platform, an integrated next-generation pipeline for crystal soaking, handling and data collection which allows crystallography-based screening of protein crystals against hundreds of fragments and compounds, at the Swiss Light Source is reported. | |||
Fast fragment- and compound-screening pipeline at the Swiss Light Source.,Kaminski JW, Vera L, Stegmann DP, Vering J, Eris D, Smith KML, Huang CY, Meier N, Steuber J, Wang M, Fritz G, Wojdyla JA, Sharpe ME Acta Crystallogr D Struct Biol. 2022 Mar 1;78(Pt 3):328-336. doi:, 10.1107/S2059798322000705. Epub 2022 Feb 21. PMID:35234147<ref>PMID:35234147</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7qu0" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Fritz G]] | [[Category: Fritz, G]] | ||
[[Category: Stegmann D]] | [[Category: Stegmann, D]] | ||
[[Category: Steuber J]] | [[Category: Steuber, J]] | ||
[[Category: Flavoprotein]] | |||
[[Category: Nadh oxidizing]] | |||